nivolumab177Lu-PSMA177Lu-PSMA-617177Lu-DOTATATEpembrolizumab
…ion-level assessment.86 Similarly, 177Lu-DOTATATE combined with nivolumab has shown tolerability and preliminary activity in pulmonary ne…
5articles mentioning drugs
14drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: 177Lu-PSMA-617 ×
177Lu-PSMA-617
This drug is selected. Its supporting articles are shown below.
Articles mentioning 177Lu-PSMA-617
5 articles · page 1 of 1177Lu-PSMA-617cyclophosphamideCymetastatic castration-resistant prostate cancermetastatic castration-resistant prostate cancer (mCRPC)mCRPCRPTNCT03873805
…responses, and extended durability. By using the two therapies (177Lu-PSMA-617 and PSCA-CAR T cells) that are FDA approved or in clinical deve…
177Lu-PSMA-617androgen receptor pathway inhibitorspoly-ADP ribose polymerase (PARP) inhibitorsprostate cancermHSPCmCRPCchemotherapyhigh risk biochemical recurrence
…chemotherapy, poly-ADP ribose polymerase (PARP) inhibitors, and 177Lu-PSMA-617 in this disease space. Finally, as patients with prostate cance…
Lutetium-177-DOTATATE177Lu-DOTATATE177Lu-PSMA-617177Lu-prostate-specific membrane antigen-617small-volume and micrometastatic disease
…diopharmaceutical pairs. Landmark clinical successes, including Lutetium-177-DOTATATE (177Lu-DOTATATE) and 177Lu-prostate-specific membrane antigen-6…
pembrolizumabNivolumabIpilimumab177Lu-PSMA177Lu-PSMA-617
… reduction in NK and B cells. When 177Lu-PSMA was combined with pembrolizumab, we saw dynamic changes in non-Treg T cell subsets (CD4+ and CD…